This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak
by Zacks Equity Research
Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.
Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?
by Zacks Equity Research
Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.
Will UnitedHealth (UNH) Dividend Hike Fail to Excite Investors?
by Zacks Equity Research
UnitedHealth's (UNH) strong financial position supports its shareholder value boosting efforts.
Company News for June 5, 2024
by Zacks Equity Research
Companies In The Article Are:CCL, CNM, HQY, CSCO.
HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.
HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 21.21% and 3.16%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in kidney care.
Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings
by Zacks Equity Research
Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.
Stay Ahead of the Game With HealthEquity (HQY) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for HealthEquity (HQY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended April 2024.
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna's (CI) Express Scripts Collaborates With CPESN USA
by Zacks Equity Research
Cigna's (CI) Express Scripts collaborates with CPESN USA in a bid to enhance care delivery for hypertension and diabetes patients.
Encompass Health (EHC) JV Opens Atlanta Rehabilitation Hospital
by Zacks Equity Research
The new facility in Georgia marks the 162nd inpatient rehabilitation hospital of Encompass Health (EHC) in the country.
Encompass Health (EHC) Opens Rehabilitation Hospital in Ballwin
by Zacks Equity Research
The 40-bed inpatient rehabilitation hospital is a JV between Encompass Health (EHC) and BJC HealthCare.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition
by Zacks Equity Research
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.